Copper Modulation as a Therapy for Alzheimer's Disease?

Abstract

The role of metals in the pathophysiology of Alzheimer's disease (AD) has gained considerable support in recent years, with both in vitro and in vivo data demonstrating that a mis-metabolism of metal ions, such as copper and zinc, may affect various cellular cascades that ultimately leads to the development and/or potentiation of AD. In this paper, we will provide an overview of the preclinical and clinical literature that specifically relates to attempts to affect the AD cascade by the modulation of brain copper levels. We will also detail our own novel animal data, where we treated APP/PS1 (7-8 months old) mice with either high copper (20 ppm in the drinking water), high cholesterol (2% supplement in the food) or a combination of both and then assessed β -amyloid (A β ) burden (soluble and insoluble A β ), APP levels and behavioural performance in the Morris water maze. These data support an interaction between copper/cholesterol and both A β and APP and further highlight the potential role of metal ion dyshomeostasis in AD.